A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter

Transgenic Research

Volumn 20, Issue 2, 2011, Pages 421-428

  Woods, Susan L ^a,b   Bishop, J Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Dct; Dopachrome tautomerase; Melanoma; MYC; Tetracycline; Transgenic

Indexed keywords

DOPACHROME ISOMERASE; GREEN FLUORESCENT PROTEIN; ISOMERASE; MYC PROTEIN; TETRACYCLINE;

ANIMAL; ARTICLE; CELL STRAIN 3T3; CYTOLOGY; EVALUATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LACTOSE OPERON; MALE; MELANOCYTE; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PROMOTER REGION; STEM CELL; TRANSGENE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LAC OPERON; MALE; MELANOCYTES; MELANOMA; MICE; MICE, TRANSGENIC; NIH 3T3 CELLS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; STEM CELLS; TETRACYCLINE; TRANSGENES;

MUS MUSCULUS;

EID: 79952448063     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-010-9421-6     Document Type: Article

References (35)

1. Beer S, Zetterberg A, Ihrie RA, Mctaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B et al (2004) Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2: e332.
2. Beermann F (1999) The tyrosinase related protein-1 (Tyrp1) promoter in transgenic experiments: targeted expression to the retinal pigment epithelium. Cell Mol Biol (Noisy-le-grand) 45: 961-968.
3. Beermann F, Schmid E, Schutz G (1992) Expression of the mouse tyrosinase gene during embryonic development: recapitulation of the temporal regulation in transgenic mice. Proc Natl Acad Sci USA 89: 2809-2813.
4. Berens C, Hillen W (2003) Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur J Biochem 270: 3109-3121.
5. Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E (2004) Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118: 635-648.
6. Botchkareva NV, Botchkarev VA, Gilchrest BA (2003) Fate of melanocytes during development of the hair follicle pigmentary unit. J Investig Dermatol Symp Proc 8: 76-79.
7. Broome Powell M, Gause PR, Hyman P, Gregus J, Lluria-Prevatt M, Nagle R, Bowden GT (1999) Induction of melanoma in TPras transgenic mice. Carcinogenesis 20: 1747-1753.
8. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'hagan R, Pantginis J, Zhou H et al (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
9. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
10. Gimenez E, Lavado A, Giraldo P, Cozar P, Jeffery G, Montoliu L (2004) A transgenic mouse model with inducible Tyrosinase gene expression using the tetracycline (Tet-on) system allows regulated rescue of abnormal chiasmatic projections found in albinism. Pigment Cell Res 17: 363-370.
11. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW (2004) Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 14: 3-11.
12. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
13. Greulich KM, Utikal J, Peter RU, Krahn G (2000) c-MYC and nodular malignant melanoma. A case report. Cancer 89: 97-103.
14. Hacker E, Irwin N, Muller HK, Powell MB, Kay G, Hayward N, Walker G (2005) Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented Tpras transgenic mice. J Invest Dermatol 125: 1074-1077.
15. Hornyak TJ, Hayes DJ, Chiu LY, Ziff EB (2001) Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. Mech Dev 101: 47-59.
16. Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding Z, Jiang S, Guney I, Kang GH, Shin E et al (2008) BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 3: e3949.
17. Jiao Z, Zhang ZG, Hornyak TJ, Hozeska A, Zhang RL, Wang Y, Wang L, Roberts C, Strickland FM, Chopp M (2006) Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. Dev Biol 296: 396-408.
18. Mackenzie MA, Jordan SA, Budd PS, Jackson IJ (1997) Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblast in the mouse embryo. Dev Biol 192: 99-107.
19. Murisier F, Guichard S, Beermann F (2006) A conserved transcriptional enhancer that specifies Tyrp1 expression to melanocytes. Dev Biol 298: 644-655.
20. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, De Fabo EC, Merlino G (2001) Neonatal sunburn and melanoma in mice. Nature 413: 271-272.
21. Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M, Sakai N, Saito N, Nishigori C, Aiba A (2008) Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27: 7162-7170.
22. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou BK, Silvers WK, Mintz B (1995) Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 92: 10152-10156.
23. Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y (2001) Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. Cancer Metastasis Rev 20: 27-32.
24. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ et al (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067.
25. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577.
26. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
27. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS et al (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34: 108-112.
28. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR (1999) Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol 17: 165-169.
29. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP (2001) Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 27: 88-93.
30. Ross DA, Laing JH, Sanders R, Wilson GD (2006) Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma. Eur J Surg Oncol 32: 80-84.
31. Steel KP, Davidson DR, Jackson IJ (1992) TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development 115: 1111-1119.
32. Walker GJ, Hayward NK (2002) Pathways to melanoma development: lessons from the mouse. J Invest Dermatol 119: 783-792.
33. Wilkie AL, Jordan SA, Jackson IJ (2002) Neural crest progenitors of the melanocyte lineage: coat colour patterns revisited. Development 129: 3349-3357.
34. Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L (2006) Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis 44: 34-43.
35. Zhao S, Overbeek PA (1999) Tyrosinase-related protein 2 promoter targets transgene expression to ocular and neural crest-derived tissues. Dev Biol 216: 154-163.